Angiotensin-converting enzyme inhibitors in patients with atherosclerosis and preserved left ventricular function: Clinical outcomes

Canadian Journal of Cardiology

Volumn 14, Issue SUPPL. D, 1998, Pages

  Pepine, Carl ^a,b  

^a UNIVERSITY OF FLORIDA   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Angiotensin converting enzyme inhibition; Quinapril Ischemic Events Trial (QUIET); Trial on Reversing ENdothelial Dysfunction (TREND)

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ISOQUINOLINE DERIVATIVE; QUINAPRIL; TETRAHYDROISOQUINOLINE DERIVATIVE;

ARTERIOSCLEROSIS; ARTICLE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DRUG EFFECT; HEART LEFT VENTRICLE FUNCTION; HUMAN; MORTALITY; PHASE 2 CLINICAL TRIAL; VASCULAR ENDOTHELIUM;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ARTERIOSCLEROSIS; CORONARY DISEASE; ENDOTHELIUM, VASCULAR; HUMANS; ISOQUINOLINES; TETRAHYDROISOQUINOLINES; VENTRICULAR FUNCTION, LEFT;

EID: 0032111368     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Lancet 1993;342:821-8.
2. Køber L, Torp-Pedersen C, Carlsen J, et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med 1995;333:1670-6.
3. Yusuf S, Pepine CJ, Garces C, et al. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. Lancet 1992;340:1173-8.
4. Pfeffer MA, Braunwald E, Moyé LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992;327:669-77.
5. Ambrosioni E, Borghi C, Magnani B. The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. The Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators. N Engl J Med 1995;332:80-5.
6. Mancini GB, Henry GC, Macaya C, et al. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease: the TREND (Trial on Reversing ENdothelial Dysfunction) study. Circulation 1996;94:258-65.
7. Schlaifer JD, Wargovich TJ, O'Neill B, et al. Effects of quinapril on coronary blood flow in coronary artery disease patients with endothelial dysfunction. The TREND Investigators. Trial on Reversing Endothelial Dysfunction. Am J Cardiol 1997;80:1594-7.
8. Schlaifer JD, Mancini GBJ, O'Neill BJ, Pitt B, Haber HE, Pepine CJ on behalf of the TREND Investigators. Influence of smoking status on angiotensin-converting enzyme inhibition-related improvement in coronary endothelial function. Eur Heart J 1997;18(Suppl):15. (Abst).
9. Pitt B, Pepine C, O'Neill H, Haber M, Pressler M, Mancini GBJ, for the TREND Investigators. Modulation of ACE inhibitor efficacy on coronary endothelial dysfunction by low density lipoprotein cholesterol. J Am Coll Cardiol 1997;29(Suppl A):70A. (Abst)
10. Cashin-Hemphill L, Dinsmore R, Chan R, et al. LDL cholesterol and angiographic progression in the QUIET trial. J Am Coll Cardiol 1997;29(Suppl A):85A. (Abst)